Cargando empresa
Keep exploring
The themes Nurix Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B US$A+
EXELExelixis, Inc.16,8B US$A+
JAZZJazz Pharmaceuticals plc15,5B US$A
TECHBIO-Techne Corp11,4B US$A+
HALOHalozyme Therapeutics, Inc.11,4B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- Collaboration revenue64 %
- License revenue36 %
Los porcentajes de ingresos son estimaciones para fiscal year ended 2025-11-30, high confidence, no cifras de un informe oficial.
Compite con
Qué vende4
Bexobrutideg (NX-5948)
An experimental oral medicine designed to make cells remove Bruton tyrosine kinase, a protein involved in some blood cancers. It is being tested in patients with blood cancers, including chronic lymphocytic leukemia.
NX-1607
An experimental oral medicine that blocks CBL-B, a cell protein that restrains immune cells. It is being tested to help immune cells attack tumors.
Zelebrudomide (NX-2127)
An experimental oral medicine designed to remove Bruton tyrosine kinase and two proteins involved in immune-cell activity. Nurix discontinued further clinical development; some patients already receiving it may continue treatment.
NX-0479 / GS-6791
A partner-developed experimental medicine designed to degrade IRAK4, a protein involved in inflammation.
Quién se lo compra4
- Gilead pays for research into drug candidates and may license candidates for further development.
- Sanofi pays for research into drug candidates and may license candidates for further development.
- Pfizer pays for research into drug candidates intended for attachment to antibodies and may license them for development.
- Roche licensed bexobrutideg and shares its development and United States commercial responsibilities with Nurix.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1Nurix has no product-sale revenue and depends on collaboration payments, license payments, and outside financing to fund its work.
- 2It relies on contract manufacturers for drug ingredients and finished medicines used in clinical trials.
- 3It relies on outside organizations to conduct clinical trials and on pharmaceutical partners to develop or sell some licensed drug candidates.
Qué podría salir mal
- 1Nurix’s drug candidates are still being tested in people; trial results, safety findings, patient enrollment, or regulatory decisions could delay or end their development.
- 2Because Nurix has no approved medicines for sale, its income depends on partner payments and licensing events, which can vary in timing and may not recur.
- 3Problems with outside manufacturers or clinical-trial contractors could interrupt drug supply or delay trials.
Estados financieros completos →
Sobre Nurix Therapeutics, Inc.
Nurix develops experimental medicines designed to make cells remove disease-related proteins, rather than simply block them. Its discovery system uses machine learning and large chemical libraries to find starting points for drugs. Pharmaceutical partners pay for research and rights to drug candidates; Nurix also develops some candidates itself. It has no approved medicines for sale.
- Sede
- San Francisco, California
- Fundada en
- 2009 (founding year, medium confidence)
- Cotiza en
- Nasdaq Global Select Market
- Cierre del ejercicio
- November 30
Construido a partir de los propios informes de Nurix Therapeutics, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
